You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither SPIE nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the SPIE website.
4 March 2020A paradigm shift in chronic wound assessment: incorporating bacterial fluorescence imaging into standard of care
The clinical signs and symptoms of infection in acute and chronic wounds are unreliable. Similarly, swab cultures are inaccurate in this population. Tissue biopsies and polymerase chain reaction (PCR) are more accurate but the results require several days to obtain. As a result, the clinician is forced to treat patients empirically. This has led to the overuse of antibiotics and the failure of advanced therapies due to unrecognized infection. To address this problem a point-ofcare diagnostic was developed to identify bacteria in acute and chronic wounds. The MolecuLight procedure (MiX) exposes the wound bed to violet light at 405 nm. Bacterial fluorophores absorb the light. In turn they fluoresce at specific wavelengths: porphyrins (red) and pyoverdines (cyan). The device detects bacteria in the wound bed at a level greater than 104 by measuring the amounts of red and or cyan fluorescence. A robust body of literature has demonstrated that elevated bacterial levels impede wound healing. The MiX can detect elevated bacteria burden in a wound allowing the clinician to address the infection. In addition, the device can guide advanced wound therapies such as antibiofilm agents, negative wound pressure therapy and preparation of the wound bed for grafting.
Thomas E. Serena
"A paradigm shift in chronic wound assessment: incorporating bacterial fluorescence imaging into standard of care", Proc. SPIE 11223, Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2020, 112230F (4 March 2020); https://doi.org/10.1117/12.2550307
The alert did not successfully save. Please try again later.
Thomas E. Serena, "A paradigm shift in chronic wound assessment: incorporating bacterial fluorescence imaging into standard of care," Proc. SPIE 11223, Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2020, 112230F (4 March 2020); https://doi.org/10.1117/12.2550307